Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Abingdon Health Plc LSE:ABDX London Ordinary Share GB00BLF79J41 ORD 0.025P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 4.50 4.00 5.00 4.50 4.50 4.50 151,277 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services - - - - 5

Abingdon Health PLC Launch of Abingdon Simply Test e-commerce website

21/07/2022 7:00am

RNS Non-Regulatory


TIDMABDX

Abingdon Health PLC

21 July 2022

Abingdon Health plc

("Abingdon" or "the Company")

Launch of Abingdon Simply Test e-commerce website

York, U.K. 21 July 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces the launch of its new B2C e-commerce website, abingdonsimplytest.com .

The Abingdon Simply Test website will provide UK and international customers with Abingdon Simply Test and Abingdon-assured third-party branded self-tests. All products will be regulatory approved and manufactured under international quality management systems.

The e-commerce site has launched with a range of tests in areas such as fertility, health and well-being and infectious disease. It is Abingdon's intention to broaden the range of available tests, with a focus on self-testing.

The Abingdon Simply Test website will provide consumers with simple, jargon-free information to enable them to make considered purchasing decisions. All tests on the abingdonsimplytest.com site will also have undergone Abingdon's 10-point evaluation covering quality, regulatory and usability requirements to provide customers with greater assurance on the quality of these tests.

Self-testing is a major growth area within the global diagnostic market and in its recent report, Future Market Insights forecast the global market for self-testing kits will be worth US $11bn by 2030(1) . Lateral flow testing has seen a significant increase in profile and familiarity following the rapid expansion of COVID-19 lateral flow self-testing during the pandemic. The increased awareness amongst the general public of lateral flow testing coupled with its benefits such as low cost and ease-of-use means that LFT testing will play a major role in the democratisation of testing and the empowerment of individuals to manage their own health.

Chris Yates, CEO of Abingdon Health plc, commented: "The healthcare landscape is changing and the increase in lateral flow testing during the COVID-19 pandemic has served as a catalyst for a paradigm shift in moving diagnostic testing out of the laboratory and into the home. Consumers are increasingly taking a more, proactive approach to managing their health and wellbeing and this is leading to the growth of the self-health and self-testing market. The launch of our Abingdon Simply Test site will provide focal point for consumers wishing to purchase lateral flow self-tests and will support people in taking an empowered role in managing their own health and wellbeing."

(1) https://www.futuremarketinsights.com/reports/self-testing-market

Enquiries:

 
 Abingdon Health plc                                  www.abingdonhealth.com/investors/ 
 Chris Yates, Chief Executive Officer                                   Via Walbrook PR 
 Melanie Ross , Chief Financial Officer 
 Dr Chris Hand, Non-Executive Chairman 
 
 Singer Capital Markets (Sole Broker and                       Tel: +44 (0)20 7496 3000 
  Nominated Adviser) 
 Peter Steel, Alex Bond, Sam Butcher (Corporate 
  Finance) 
 Tom Salvesen (Corporate Broking) 
 
 Walbrook PR Limited                Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com 
 Paul McManus / Phillip                      Mob: +44 (0)7980 541 893 / +44 (0)7867 984 
  Marriage                                                                          082 
 Alice Woodings                                                Mob: +44 (0)7407 804 654 
 
 

About Abingdon Health

Abingdon Health is a world leading developer and manufacturer of high-quality lateral flow rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx(R) , a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: www.abingdonhealth.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAPPUPCMUPPGMU

(END) Dow Jones Newswires

July 21, 2022 02:00 ET (06:00 GMT)

1 Year Abingdon Health Chart

1 Year Abingdon Health Chart

1 Month Abingdon Health Chart

1 Month Abingdon Health Chart
Your Recent History
LSE
ABDX
Abingdon H..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20221209 23:56:02